

**IOTest[®] 3
CD34-FITC /
CD117-PE /
CD45-ECD**

REF A07718
25 tests; 0.5 mL
20 µL / test



IOTest 3
Conjugated Antibodies



ENGLISH	Specifications of constituent 1	Specifications of constituent 2	Specifications of constituent 3
Specificity	CD34	CD117	CD45
Clone	581	104D2D1	J33
Hybridoma	NSO x Balb/c	SP2/0 x Balb/c	NS1 x Balb/c
Immunogen	KG-1a cell line + human CD34 ⁺ leukaemia	MOLM-1 leukaemic cell line	Laz 221 cell line
Immunoglobulin	IgG1	IgG1	IgG1
Species	Mouse	Mouse	Mouse
Source	Ascites	Ascites	Ascites
Purification	Protein A affinity chromatography	Protein A affinity chromatography	Protein A affinity chromatography
Fluorochrome	Fluorescein isothiocyanate (FITC)	R Phycoerythrin (PE)	R Phycoerythrin-Texas Red [®] -X (E CD [™])
λ excitation	488 nm	488 nm	488 nm
Emission peak	525 nm	575 nm	613 nm
Buffer	PBS pH 7.2 plus 2 mg / mL BSA and 0.1% NaN ₃		

USE

This fluorochrome conjugated antibody mixture is suitable for multiparametric analysis using flow cytometry. It permits the detection of the expression of antigens CD34, CD117 and CD45 on cells of haematopoietic origin.

PRINCIPLE

This test is based on the ability of specific monoclonal antibodies to bind to the antigenic determinants expressed by certain cells of hematopoietic origin.

Specific staining is performed by incubating the sample with the IOTest 3 reagent. The mature red cells are then removed by lysis and the leucocytes and hematopoietic progenitors, which are unaffected by this process, are analyzed by flow cytometry.

The flow cytometer analyzes light diffusion and the fluorescence of cells. It makes possible the localization of cells within the electronic window defined on a histogram, which correlates the orthogonal diffusion of light (Side Scatter or SS) with the fluorescence of ECD, corresponding to CD45 staining. Other histograms combining two of the different parameters available on the cytometer are also used in the gating stage. The cell population thus gated is subdivided into sub-populations, using the two other fluorescences.

In this way, the positively-stained cells are distinguished from the unstained cells. The results are expressed as a percentage of fluorescent cells in relation to all the events acquired by the gating.

EXAMPLES OF CLINICAL APPLICATIONS

The simultaneous analysis of CD34 and CD117 antigens aids in the characterisation of blast cells of myeloid origin: the degree of immaturity is defined by the expression of CD34 and the myeloid origin by the co-expression of CD117 (1 – 6).

Blast cells are targeted using a Side Scatter histogram versus CD45 (1, 2, 7). A slight to average expression by the CD45 antigen is characteristic of blast cells of myeloid origin (in acute myeloid leukaemias AML), whereas negative to weak expression is observed on the surface of blast cells of lymphoid origin (in acute lymphoblastic leukaemias, ALL) (1).

STORAGE AND STABILITY

The conjugated liquid forms must be kept at between 2 and 8°C and protected from light, before and after the vial has been opened.

Stability of closed vial: see expiry date on vial.

Stability of opened vial: the reagent is stable for 90 days.

PRECAUTIONS

1. Do not use the reagent beyond the expiry date.
2. Do not freeze.
3. Let it come to room temperature (18 – 25°C) before use.
4. Minimize exposure to light.
5. Avoid microbial contamination of the reagents, or false results may occur.
6. Antibody solutions containing sodium azide (NaN₃) should be handled with care. Do not take internally and avoid all contact with the skin, mucosa and eyes. Furthermore, in an acid medium, sodium azide can form the potentially dangerous hydrazoic acid. If it needs to be disposed of, it is recommended that the reagent be diluted in a large volume of water before pouring it into the drainage system so as to avoid the accumulation of sodium azide in metal pipes and to prevent the risk of explosion.
7. All blood samples must be considered as potentially infectious and must be handled with care (in particular: the wearing of protective gloves, gowns and goggles).
8. Never pipette by mouth and avoid all contact of the samples with the skin, mucosa and eyes.
9. Blood tubes and disposable material used for handling should be disposed of in ad hoc containers intended for incineration.

SPECIMENS

Venous blood or bone marrow samples must be taken using sterile tubes containing an EDTA salt as the anticoagulant. The use of other anticoagulants is not recommended.

The samples should be kept at room temperature (18 – 25°C) and not shaken. The sample should be homogenized by gentle agitation prior to taking the test sample.

The samples must be analyzed within 24 hours of venipuncture.

METHODOLOGY

NECESSARY MATERIAL NOT SUPPLIED

- Sampling tubes and material necessary for sampling.
- Automatic pipettes with disposable tips for 20, 100 and 500 µL.
- Plastic haemolysis tubes.
- Calibration beads: Flow-Set[™] Fluorospheres (Ref. 6607007).
- To obtain optimal results, the following reagents are recommended:
 - Lysing reagent: IOTest 3 Lysis Solution (Ref. A07799).
 - Fixation reagent: IOTest 3 Fixative Solution (Ref. A07800).
 - One of the following IOTest 3 negative controls:

Neg.Ctrl.-FITC /Neg.Ctrl.-PE/CD45-ECD (Ref. A07729) or
Neg.Ctrl.-FITC /Neg.Ctrl.-PE/Neg.Ctrl.-ECD (Ref. A07732).

- Buffer (PBS: 0.01 M sodium phosphate; 0.145 M sodium chloride; pH 7.2).
- Centrifuge.
- Automatic agitator (Vortex type).
- Flow cytometer.

PROCEDURE

For each sample analyzed, in addition to the test tube, one control tube is required in which the cells are mixed with the selected IOTest 3 negative control (Ref. A07729 or A07732).

1. Add 20 µL of specific IOTest 3 conjugated antibodies to each test tube, and 20 µL of the appropriate negative control to each control tube.
2. Add 100 µL of the test sample to the 2 tubes. Vortex the tubes gently.
3. Incubate for 15 to 20 minutes at room temperature (18 – 25°C), protected from light.
4. Then perform, if necessary, lysis of the red cells by adding 2 mL of IOTest 3 Lysis Solution (Ref. A07799) at its working concentration (1X). Vortex immediately and incubate for 10 minutes at room temperature, protected from light. If the sample does not contain red cells, add 2 mL of PBS.
5. Centrifuge for 5 minutes at 300 x g at room temperature.
6. Remove the supernatant by aspiration.
7. Resuspend the cell pellet using 3 mL of PBS.
8. Repeat stage 5.
9. Remove the supernatant by aspiration and resuspend the cell pellet using:
 - 0.5 mL or 1 mL of IOTest 3 Fixative Solution (Ref. A07800) at its working concentration (1X), if the preparations are to be kept for more than 2 hours and for less than 24 hours,
 - 0.5 mL or 1 mL of PBS without formaldehyde, if the preparations are to be analyzed within 2 hours.

NOTE : In all cases, keep the preparations between 2 and 8°C and protected from light.

PERFORMANCE

SPECIFICITY

CD34 is a transmembrane monomeric glycoprotein with a molecular weight of approximately 110 kDa (8 – 10). It is the most commonly used marker for identifying progenitor cells of human haematopoiesis (11, 12). This antigen is expressed by almost all haematopoietic progenitor cells as well as by pluripotent cell strains (13 – 15). Thus, the CD34 antigen is normally only expressed by 1 to 5 % of bone marrow cells or those from cord blood (13) and by 0.1 to 0.5 % of cells in the peripheral blood (16). The molecule is also expressed by vascular endothelial cells (17, 18), as well as by stromal cells (and their precursors) of bone marrow (19).

The monoclonal antibody (mAb) 581 recognizes a class III epitope of the CD34 molecule (20). MAb 581 was assigned to CD34 during the 5th HLDA Workshop on Human Leucocyte Differentiation Antigens held in Boston, USA, in 1993 (WS Code: MA027, Section M) (20).

The CD117 antigen is a transmembrane glycoprotein of 145 kDa coded by means of the proto-oncogen c-kit (21).

Within the haematopoietic compartment, the CD117 molecule is expressed on approximately 50 % of CD34⁺ progenitors engaged in erythrocytic (22), myelo-monocytic and megakaryocytic differentiation (23, 24). Apart from on mastocytes, expression of the CD117 antigen is not found at the mature haematopoietic cell level.

MAb 104D2D1 was assigned to CD117 during the 6th HLDA Workshop held in Kobe, Japan, in 1996 (WS Code: C-30. Section C) (23).

The CD45 molecule is expressed on the surface of all human leucocytes, but is absent from mature red blood cells (25). The density of expression of the CD45 antigen on lymphocytes is greater than that observed on monocytes and neutrophils (26).

MAb J33 reacts with all the isoforms of CD45 (180 to 220 kDa): it is therefore referenced as a pan-leucocytic marker. It was assigned to CD45 during the 3rd HLDA Workshop, Oxford, England, in 1986 (WS Code: 818, Section NL) (27).

LINEARITY

To test the linearity of staining for the specificities of this reagent, a positive cell line and a negative cell line were mixed in different proportions with a constant final number of cells, so that the positive line/negative line ratio of the mixture ranged from 0 to 100%.

Aliquots were stained using the procedure described above and linear regression between the expected values and the observed values was calculated.

Specificity	Linear regression	Linearity (R ²)
CD34	Y = 0.98 X + 0.60	0.999
CD117	Y = 0.99 X + 1.20	0.999
CD45	Y = 0.98 X + 0.84	0.999

EXPECTED VALUES

Each laboratory must compile a list of reference values based upon a group of healthy donors from the local population. This must be done by taking age, sex and ethnic group into account, as well as any other potential regional differences.

In our laboratories, the whole blood samples of 10 healthy adults were treated using the reagent described above. Given the rarity of cells positive for CD34 and CD117 in peripheral blood, the expected values for these specificities are not given. The results obtained for CD45 on the leucocytic sub-populations of interest in these 10 donors are shown in the tables below:

Lymphocytes	Number	Mean (%)	SD	CV (%)
CD45 ⁺	10	95.75	3.17	3.3

Monocytes	Number	Mean (%)	SD	CV (%)
CD45 ⁺	10	96.69	1.85	1.9

Granulocytes	Number	Mean (%)	SD	CV (%)
CD45 ⁺	10	99.86	0.15	0.2

INTRA-LABORATORY REPRODUCIBILITY

On the same day and using the same cytometer, 12 measurements of the percentage of positive cells were carried out on target populations expressing one and/or other of these three antigens (human KG-1a and/or MO7E line). The results obtained are summarized in the following table:

KG-1a + MO7E	N°	Mean (%)	SD	CV (%)
KG-1a/CD34 ⁺	12	70.31	0.44	0.62
MO7E CD117 ⁺	12	26.76	0.4	1.46
KG-1a + MO7E / CD45 ⁺	12	99.43	0.09	0.09

INTER-LABORATORY REPRODUCIBILITY

On the same day and on the same positive target (mixture of KG-1a and MO7E cell lines), 12 measurements of the percentage of positive cells were carried out by two technicians and the preparations analysed using two different cytometers. The results obtained are summarized in the following tables:

Cytometer n°1:

KG-1a + MO7E	Number	Mean (%)	SD	CV (%)
CD34 ⁺	12	70.31	0.44	0.62
CD117 ⁺	12	26.76	0.4	1.46
CD45 ⁺	12	99.43	0.09	0.09

Cytometer n°2:

KG-1a + MO7E	Number	Mean (%)	SD	CV (%)
CD34 ⁺	12	69.52	0.54	0.8
CD117 ⁺	12	27.68	0.53	1.9
CD45 ⁺	12	99.86	0.05	0.1

LIMITATIONS OF THE TECHNIQUE

- Flow cytometry may produce false results if the cytometer has not been aligned perfectly, if fluorescence leaks have not been correctly compensated for and if the regions have not been carefully positioned.
- It is preferable to use a RBC lysis technique with a washing step as this reagent has not been optimized for "no wash" lysis techniques.
- Accurate and reproducible results will be obtained as long as the procedures used are in accordance with the technical insert leaflet and compatible with good laboratory practices.
- The conjugated antibodies of this reagent are calibrated so as to offer the best specific signal/non-specific signal ratio. Therefore, it is important to adhere to the reagent volume/sample volume ratio in every test.
- In the case of a hyperleucocytosis, dilute the blood in PBS so as to obtain a value of approximately 5×10^9 leucocytes/L.
- In certain disease states, such as severe renal failure or haemoglobinopathies, lysis of red cells may be slow, incomplete or even impossible. In this case, it is advisable to isolate mononucleated cells using a density gradient (Ficoll for example), prior to staining.
- CD45-negative or very weakly-positive acute lymphoblastic leukaemia have been described. For these, the lymphocytic origin of the blast cells should be confirmed using other markers.

MISCELLANEOUS

See the Appendix for examples and references.

TRADEMARKS

The Beckman Coulter logo, COULTER, ECD, EPICS, EXPO, Flow-Set, IOTest, System II, and XL are the registered trademarks of Beckman Coulter Inc.

Texas Red is a registered trademark of Molecular Probes Inc.

MANUFACTURED BY:

IMMUNOTECH
a Beckman Coulter Company
130 avenue de Lattre de Tassigny
B.P. 177 – 13276 Marseille Cedex 9
France
Customer Services: (33) 4 91 17 27 27

www.beckmancoulter.com




APPENDIX TO REF A07718

EXAMPLES

Conjugated Antibodies (Ref. A07718). Lysis and fixation are with IOTest 3 Lysing Solution (Ref. A07799) and IOTest 3 Fixative Solution (Ref. A07800) respectively. All events acquired are shown. Gated events are shown in dark in all histograms.

Acquisition is with a COULTER® EPICS® XL™ flow cytometer equipped with System II™ software. Analysis is with EXPO™ Cytometer software (Ref. 6605434).



REFERENCES

1. Borowitz, M.J., Guenther, K.L., Shults, K.E., Stelzer, G.T., "Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis", 1993, *Am. J. Clin. Pathol.*, 100, 534-540.
2. Seltzer, G.T., Shults, K.E., Loken, M.R., "CD45 gating for routine flow cytometric analysis of human bone marrow specimens", 1993, *Acad. Sciences*, 265-280.
3. Bene, M.C., Castoldi, G., Knapp, W., Ludwig, W.D., Matutes, E., Orfao, A., van't Veer, M.B., "Proposals for the immunological classification of acute leukemias", 1995, *Leukemia*, 9, 1783-1786.
4. Borowitz, M.J., Bray, R., Gascoyne, R., Melnick, S., Parker, J.W., Picker, L., Stetler-Stevenson, M., "U.S. Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Data analysis and interpretation", 1997, *Cytometry*, 30, 236-244.
5. Stewart, C.C., Behm, F.G., Carey, J.L., Cornbleet, J., Duque, R.E., Hudnall, S.D., Hurtubise, P.E., Loken, M., Tubbs, R.R., Wormsley, S., "U.S. Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Selection of antibody combinations", 1997, *Cytometry*, 30, 231-235.
6. Rothe, G., Schmitz, G., Adorf, D., Barlage, S., Gramatzki, M., Höffkes, H.G., Janossy, G., Knüchel, R., Ludwig, W.D., Nebe, T., Nerl, C., Orfao, A., Serke, S., Sonnen, R., Tichelli, A., Wörmann, B., "Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies", 1996, *Leukemia*, 10, 877-895.
7. Lacombe, F., Durrieu, F., Briaux, A., Dumain, P., Belloc, Bascans, E., Reiffers, J., Boisseau, M.R., Bernard, P., "Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia", 1997, *Leukemia*, 11, 1878-1886.
8. Sutherland, Keating, A., "The CD34 antigen: Structure, biology and potential clinical applications", 1992, *J. Hematotherapy*, 1, 115-129.
9. Krause, D.S., Fackler, M.J., Civin, C.I., Stratford, M., "CD34: Structure, biology and clinical utility", 1996, *Blood*, 1, 87, 1-13.
10. To, L.B., Haylock, D.N., Simmons, P.J., Juttner, C.A., "The biology and clinical uses of blood stem cells", 1997, *Blood*, 89, 2233-2258.
11. Andrews, R.G., Singer, J.W., Bernstein, I.D., "Human hematopoietic precursors in long-term culture. Single CD34⁺ cells that lack detectable T cell, B cells and myeloid cell antigens produce multiple colony-forming cells when cultured with marrow stromal cells", 1990, *J. Exp. Med.*, 172, 355-358.
12. Lansdorp, P.M., Sutherland, H.J., Eaves, C.J., "Selective expression of CD45 isoforms on functional subpopulations of CD34⁺ hemopoietic cells from human bone marrow", 1990, *J. Exp. Med.*, 172, 363-366.
13. Civin, C.I., Strauss, L.C., Brovall, c., Jackler, M.J., Schwartz, J.F., Shaper, J.H., "Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells", 1984, *J. Immunol.*, 133, 157-165.
14. Berenson, R.J., Bensinger, W.I., Hill, R.S., Andrews, R.G., Garcia-Lopez, J., Kalamaz, D.F., Still, B.J., Spitzer, G., Buckner, C.D., Bernstein, I.D., Thomas, E.D., "Engraftment after infusion of CD34⁺ marrow cells in patients with breast cancer or neuroblastoma", 1991, *Blood*, 77, 1717-1722.
15. Terstappen, L.W.M.M., Huang, S., Safford, M., Lansdorp, P.M., Loken, M.R., "Sequential generation of hematopoietic colonies derived from single nonlineage-committed CD34⁺CD38⁻ progenitor cells", 1991, *Blood*, 77, 1218-1227.
16. Siena, S., Bregni, M., Brando, B., Ravignani, F., Bonadonna, G., Gianni, A.M., "Circulation of CD34⁺ hematopoietic stem cells in the peripheral blood of high dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte macrophage colony stimulating factor", 1989, *Blood*, 74, 1905-1914.
17. Fina, L., Molgaard, H.V., Robertson, d., Bradley, N.J., Monaghan, P., Delia, D., Sutherland, D.R., Baker, M.A., Greaves, M.F., "Expression of the CD34 gene in vascular endothelial cells", 1990, *Blood*, 75, 2417-2426.
18. Delia, D., Lampugnani, M.G., Resnati, M., Dejana, E., Ajello, A., Fontanella, E., Soligo, D., Pierotti, M.A., Greaves, M.F., "CD34 expression is regulated reciprocally with adhesion molecules in vascular endothelial cells in vitro", 1993, *Blood*, 81, 1001-1008.
19. Simmons, P.J., Torok-Storb, B., "CD34 expression by stromal precursors in normal human adult bone marrow", 1991, *Blood*, 78, 2848-2853.
20. Greaves, M.F., Tittley, I., Colman, S.M., Bühring, H.-J., Campos, L., Castoldi, G.L., Garrido, F., Gaudernack, G., Girard, J.-P., Inglès-Esteve, J., Invernizzi, R., Knapp, W., Lansdorp, P.M., Lanza, F., Merle-Béral, H., Parravicini, C., Razak, K., Ruiz-Cabello, F., Springer, T.A., van der Schoot, C.E., Sutherland, D.R., "CD34 cluster Workshop report", 1995, *Leucocyte Typing V, White Cell Differentiation Antigens*. Schlossman, S.F., et al., Eds., Oxford University Press, 840-846.
21. Sperling, C., Schwartz, S., Büchner, T., Thiel, E., Ludwig, W.-D., "Expression of the stem cell factor receptor c-kit (CD117) in acute leukemias", 1997, *Haematologica*, 82, 617-621.
22. Uoshima, N., Ozawa, M., Kimura, S., Tanaka, K., Wada, K., Kobayashi, Y., Kondo, M., "Changes in c-Kit expression and effects of SCF during differentiation of human erythroid progenitor cells", 1995, *Br. J. Haematol.*, 91, 30-36.
23. Ashman, L.K., Cambareri, A.C., Nguyen, L., Bühring, H.-J., "CD117 Workshop panel report", 1997, *Leucocyte Typing VI, White Cell Differentiation Antigens*. Kishimoto, T., et al, Eds., Garland Publishing, Inc., 816-818.
24. Escribano, L., Ocqueteau, M., Almeida, J., Orfao, A., San Miguel, J.F., "Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis", 1998, *Leuk. Lymphoma*, 30, 459-466.
25. Sewell, W.A., Cooley, M.A., Hegen, M., "CD45 Workshop Panel Report", 1997, *Leucocyte Typing VI, White Cell Differentiation Antigens*. Kishimoto, T., et al, Eds., Garland Publishing, Inc., 499-502.
26. Poppema, S., Lai, R., Visser, L., Yan, X.J., "CD45 (Leucocyte Common Antigen) expression in T and B lymphocyte subsets", 1996, *Leuk. Lymphoma*, 20, 217-222.
27. Cobbold, S., Hale, G., Waldmann, H., "Non-lineage, LFA-1 family, and leukocyte common antigens: New and previously defined clusters", 1987, *Leucocyte Typing III, White Cell Differentiation Antigens*, McMichael A.J., et al., Eds., Oxford University Press, 788-803.